Amneal Pharmaceuticals Highlights Growth and Acquisition at Goldman Sachs Healthcare Conference
Amneal Pharmaceuticals, Inc. (AMRX) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Seeking Alpha
Image: Seeking Alpha
At the Goldman Sachs 47th Annual Global Healthcare Conference, Chirag Patel, Co-CEO of Amneal Pharmaceuticals, discussed the company's strategic acquisition of Kashiv BioSciences and anticipated growth in their product lines, particularly hormonal and pain patches, projecting a potential increase in sales by 10-15%.
- 01Amneal Pharmaceuticals announced a significant acquisition of Kashiv BioSciences to enhance its biosimilars business.
- 02Chirag Patel highlighted a projected growth of 10-15% in in-line products, a shift from the usual decline of 4-5%.
- 03The growth is primarily driven by hormonal and pain patches manufactured in Garwood, New Jersey.
- 04The company sees this acquisition as a strategic move to vertically integrate their operations and expand their market presence.
- 05The conference provided a platform for Amneal to connect with industry leaders and investors.
Advertisement
In-Article Ad
At the Goldman Sachs 47th Annual Global Healthcare Conference held on June 9, 2026, Chirag Patel, Co-CEO of Amneal Pharmaceuticals, shared insights into the company's recent acquisition of Kashiv BioSciences, aimed at strengthening their biosimilars segment. Patel expressed enthusiasm about the company's growth trajectory, particularly in their in-line products, which are expected to rise by 10-15%, a notable turnaround from the typical 4-5% decline seen in previous years. The growth is largely attributed to the success of hormonal and pain patches, which are produced at their facility in Garwood, New Jersey. Patel emphasized the importance of this acquisition in vertically integrating their operations and enhancing their competitive edge in the market. The conference served as an opportunity for Amneal to engage with key stakeholders in the biopharma sector, showcasing their strategic priorities and growth drivers for the upcoming months and beyond.
Advertisement
In-Article Ad
The growth in Amneal's product lines could lead to increased production and job stability at their Garwood, New Jersey facility.
Advertisement
In-Article Ad
Reader Poll
What do you think about Amneal's acquisition strategy?
Connecting to poll...
Read the original article
Visit the source for the complete story.